PSI and AlphaSYNT: Pioneers on the Path to Sustainable Energy Technologies
AlphaSYNT and PSI are receiving support from the Aargau Cantonal Research Fund to scale up the reactor design to a double-digit MW capacity.
ESA Opens Innovation Center in Switzerland
The European Space Agency (ESA) is launching the "European Space Deep-Tech Innovation Centre" (ESDI) in collaboration with PSI, located in Park Innovaare.
Technology Briefing: AI in Manufacturing Processes
When: Thursday, November 28, 2024, 13.30 –18.00h
Where: Paul Scherrer Institut, 5232 Villigen PSI, Auditorium (PSI West)
Register today – we look forward to seeing you!
PSI at this year's "Open-i"!
Open-i is Switzerland's leading innovation platform and will be held on November 21 & 22 in Zurich – PSI will be there as a "Science Partner"!
XRnanotech wins Swiss Excellence Product Award 2024
The PSI spin-off XRnanotech AG has won the Swiss Excellence Product Award 2024 in the SME category and was recognized for its outstanding developments in the field of Fresnel lenses and diffractive optical elements (DOEs).
Happy Birthday, DECTRIS!
DECTRIS AG was founded around 18 years ago as a spin-off of the Paul Scherrer Institute (PSI) and has since established itself as a leading provider of solutions in X-ray and electron detection. The impressive development of the company is the result of innovative research, outstanding teamwork, and a clear focus on market needs.
PSI Spin-offs shine at the TOP 100 Swiss Startup Award!
Two spin-offs from the Paul Scherrer Institute (PSI) have made it into the TOP 100 Swiss Startups 2024!
SLS 2.0: Empowering Industry with Cutting-Edge Technology
The "SLS 2.0" upgrade will elevate the Swiss Light Source (SLS) at PSI to a new technological level, ensuring it remains a global leader in research. This upgrade not only enhances scientific capabilities but also opens new possibilities for the industrial sector.
For over two decades, the SLS has delivered extremely bright, highly focused X-ray beams, enabling researchers to analyze materials at the atomic level. With SLS 2.0, this large research facility will reach even greater performance levels – offering a significant advantage for companies invested in research and development.
PSI at the Sustainable Switzerland Forum
The Sustainable Switzerland Forum, the sustainability conference organized by NZZ Connect, is taking place today in Bern, with PSI participating as a partner.
PSI and Metafuels: Pioneers for Sustainable Aviation Fuel
PSI focuses on sustainable aviation: In collaboration with the climate start-up Metafuels, PSI is developing the aerobrew technology to produce sustainable aviation fuel (eSAF) from renewable energy sources.
Swiss Technology Award
As part of the annual Swiss Innovation Platform "open-i" in Zurich in November, the "Swiss Technology Award" will once again be presented this year in three categories.
Proxima Fusion moves to Park Innovaare
Proxima Fusion and the Paul Scherrer Institute (PSI) have signed a framework agreement to develop high-temperature superconductor magnet technology (HTS).
leadXpro and Golgi Neurosciences Work on GPR65 Modulators
leadXpro, a spin-off company of PSI active in the field of biotechnology, and Golgi Neurosciences, a biotech incubator based in Milan, have announced a partnership to develop therapies for neurodegenerative diseases. They are working on positive and negative modulators of the GPR65 receptor, which plays a role in neuroinflammation, multiple sclerosis, Parkinson's disease, fibrosis, cancer, and inflammatory bowel disease.
Association for medical research and innovation founded in the Canton of Aargau
On June 3, 2024, Kantonsspital Aarau, Kantonsspital Baden, Hirslanden Klinik Aarau, ETH Zurich, Empa, and the Paul Scherrer Institute (PSI) founded the "Association for Medical Research and Innovation in the Canton of Aargau." This project aims to intensify the transfer of knowledge between research and clinical practice, making medical innovations more quickly accessible.
PSI Fellow receives support from UBS Culture Foundation
The UBS Culture Foundation has awarded physicist Sebastian Gliga from the Paul Scherrer Institute a grant to digitize an irrecoverable, historical recording of B.B. King from his 1980 concert at the Montreux Jazz Festival.
Switzerland Innovation Park Innovaare celebrates opening
An important milestone has been reached: yesterday, Thursday 25 April 2024, Switzerland Innovation Park Innovaare was officially opened in the presence of Federal Councillor Guy Parmelin and numerous guests from industry, science and politics. In just four years, Switzerland Innovation Park Innovaare in Villigen next to the Paul Scherrer Institute (PSI) has become a state-of-the-art, research-orientated innovation park with 23,000 m2 of clean rooms, laboratories, precision workshops, offices and meeting rooms. The main tenant and strategic partner is PSI. To date, around 80% of the total space has been let.
Event for Female Founders and Professionals: Navigating Networking and Building Alliances
What networks are crucial when starting-up? What strategies can help you build meaningful connections with industry leaders? How can you boost your networking skills to realize your professional goals?
Progress through Strategic Collaboration
The Paul Scherrer Institute PSI and the Finnish company PiBond are collaborating to commercially leverage advanced semiconductor products manufactured using EUV lithography.
InterAx Biotech revolutionises drug development with new modes of action
InterAx Biotech AG, a spin-off company of the Paul Scherrer Institute and ETH, is setting new standards in drug development with its advanced AI platform. By uncovering novel cellular signalling pathways, the company is paving the way for innovative therapies in the fields of diabetes, obesity and immuno-oncology.
PSI at the this year’s KMU Swiss Symposium!
This year's KMU Swiss Symposium will take place in Baden, Kt. Aargau, on 21 March - we are pleased to be there again this year!
PSI at the this year's Swiss Innovation Forum!
Networking and exchange, inspiration and new ways of thinking can make an important contribution to innovation. That’s why we as PSI support the this year’s edition of the Swiss Innovation Forum (SIF) 2023 in Basel as a partner.
On 30 November, motivated start-ups, committed investors and courageous idea generators meet at the Congress Centre Basel. In a cross-sector exchange, they develop new ideas to drive the Swiss innovation landscape forward.
Highlights of the programme:
💡 Keynotes by Catrin Hinkel (CEO, Microsoft Schweiz), Jürgen Geuter (Tech De-Evangelist & Co-Founder, Otherwise Network), Prof. Dr. Gregor Hasler (Professor, Chefarzt, Universität Freiburg und Freiburger Netzwerk für Psychische Gesundheit (Schweiz)) and many more.
💡 Presentation of the Swiss Technology Award 2023, the most important technology prize in Switzerland.
💡 Experience Zone with exciting cases from Switzerland as a country of innovation.
PSI will be there: Together with ETH Zurich, we will be presenting the exciting topic of "Quantum Computing" at our stand at FutureExpo this year! Looking forward to meeting you there!
Detailed information and registration for the conference at www.swiss-innovation.com/en/
Technology Briefing: The Journey through Energy Storage Technologies
Our next Technology Briefing on Energy Storage Technologies will be held at CSEM in Neuchatel on 16 November 2023.
Industry Seminar ANAXAM: "Neutron and Synchrotron X-ray Diffraction for Industrial Applications"
The technology transfer centre ANAXAM offers industry access to analytical methods with neutron and synchrotron radiation and supports its industrial customers in being able to offer innovative and high-quality products. SMEs in particular benefit from ANAXAM and can thereby strengthen their competitiveness.
ANAXAM has already helped numerous customers to improve their production processes and products.
The seminar "Introduction to Neutron and Synchrotron X-ray Diffraction for Industrial Applications" aims to introduce the basic principles of Diffraction and how Diffraction analytics using Neutrons and Synchrotron X-rays facilitate investigating industrial materials.
Benefit from ANAXAM's know-how and competences and learn how to take your company a step forward with ANAXAM.
WHEN: 22 November 2023; 2:00 - 3:30 p.m.
The seminar takes place online and is free of charge.
More information and link to register:
https://www.anaxam.ch/de/events/introduction-neutron-and-synchrotron-x-ray-diffraction-industrial-applications
The language of the seminar is English.
TOP 100 Swiss Startup Award: Araris Biotech AG ranks TOP 14!
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology.
At the this year’s edition of the TOP 100 Swiss Startup Award, where Switzerland’s best startups with the greatest potential are celebrated, Araris ranks TOP14!
It is now the fifth year in a row, starting 2019, that Araris is selected by a Jury of investors and startup experts.
What a great success for Araris, after positions 19 in 2022 and 11 in 2021.
We congratulate Philipp Spycher (CEO) and his team for this great achievement!
ANAXAM Industry Seminar: "Neutron and Synchrotron Imaging for Industrial Applications"
The Technology Transfer Centre ANAXAM offers industry access to analytical methods with neutron and synchrotron radiation and supports its industrial customers in being able to offer innovative and high-quality products.
The seminar "Introduction to Neutron and Synchrotron Imaging for Industrial Applications" aims to introduce the basic principles of imaging and to show how imaging analytics with neutron and synchrotron radiation facilitates the investigation of industrial materials.
Benefit from ANAXAM's know-how and competences and learn how to take your company a step forward with ANAXAM!
WHEN: 15 November 2023; 2:00 - 3:30 p.m.
The seminar takes place online and is free of charge.
More information and link to register:
https://www.anaxam.ch/de/events/introduction-neutron-and-synchrotron-x-...
The language of the seminar is English.
Earlier detection of breast cancer
Promising method for diagnosing breast cancer: a research team from PSI, ETH Zurich, the Cantonal Hospital Baden and the University Hospital Zurich has further developed and improved the method for the early detection of breast cancer and promises hope for diagnostics.
Breast cancer is still the most common type of cancer in women today. In the course of her life, one in nine women is affected. In Switzerland alone, about 6000 women are diagnosed with breast cancer every year. This means that this type of cancer accounts for about one third of all cancer diagnoses in women.
The mammography used up to now only provides two-dimensional images, which often leads to unclear or incorrect diagnoses. The improved procedure based on X-ray phase contrast should not only provide considerably more reliable results, but will also be less painful for patients. Tumours should now be detected earlier than before due to the three-dimensional representation of the images, which in turn means that appropriate therapy can be started earlier and valuable time can be gained.
The research team plans to start clinical trials by the end of 2024, as soon as the prototype of the necessary device is ready for use. A project duration of one to two years is planned for the test series that will then follow, until the development of a commercial device could begin.
More information can be found here:
Promising collaboration with ITM in the field of cancer therapy
PSI and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, have entered into a collaboration for the joint development of the production of a novel therapeutic radionuclide, terbium-161. In this collaboration, PSI and ITM will combine their respective technologies and expertise in the production of terbium-161, including clinical and commercial use in targeted radionuclide therapy for the treatment of cancer. The goal is to be able to offer cancer patients new and better treatment options.
Terbium-161 has been identified as a very promising therapeutic isotope for targeted radionuclide therapy in cancer due to its excellent physicochemical properties: The convincing therapeutic capabilities of terbium-161 have been demonstrated in various preclinical studies at PSI. The collaboration with ITM - a pioneer and major player in the field of radiopharmaceutical applications - aims to combine PSI's long-standing research with ITM's extensive knowledge to drive further innovation in radionuclide therapy.
With this collaboration, ITM expands its research and production portfolio alongside Lutetium-177 and Actinium-225, which are currently the most widely used medical radioisotopes for targeted radionuclide therapy and which ITM supplies to hospitals and pharmaceutical partners worldwide.
Industry-Event: «Advanced Manufacturing» - What may added value cost?
ANAXAM, cross-ING and inspire AG cordially invite interested industry representatives to their information event on 29 June 2023 on the topic of "AM in the field of tension - what can added value cost?”
Successful AM solutions are characterized by the fact that they are understood and supported by the entire company. The additional benefits made possible by additive manufacturing - the "added value" - must be transported and communicated from the development department through marketing and sales to the customer.
PSI and Park Innovaare at the this year’s Swiss Nano Convention!
From 15 to 16 June 2023, the Swiss NanoConvention will take place in Neuchâtel. The platform offers the opportunity to exchange, discuss and network with key players from science and industry.
PSI will be there - visit us at our joint stand with Park Innovaare, the innovation park next to PSI, and find out more about how we can support industry and SMEs with their technical challenges and innovation processes. In combination with the possibilities of state-of-the-art material analytics, we can help you to improve both your products and your manufacturing processes.
XRnanotech, one of our spin-off companies, will also be present at our booth.
The main topics of the conference include Nano for Medtec, Life Sciences, Optics, Quantum Computing and Imaging. The two-day programme will feature plenary lectures, thematic sessions, discussion platforms and ample opportunity for in-depth and informal networking. A poster session and an exhibition are also planned.
We are looking forward to meeting you at booth no 26 soon!
Detailed information on the event can be found at:
https://swissnanoconvention.ch/2023/
Robert Rudolph new CEO of innovAARE AG
Change at the top of innovAARE AG, the operating company of Park Innovaare in Villigen: The Board of Directors has elected Mr. Robert Rudolph as the new CEO, who will take office at the beginning of April 2023. The retiring CEO Dr. Benno Rechsteiner is leaving Park Innovaare at his own request to take on a new challenge. Dr. Rechsteiner has been employed at innovAARE AG since June 2018 and has contributed significantly to important milestones for innovAARE AG: In summer 2019, an investor for the new construction of Park Innovaare was found in the form of CPV/CAP Pensionskasse Coop. In autumn of the same year, the groundbreaking ceremony for the building complex was celebrated. Under Dr. Rechsteiner's leadership, the development and expansion of the innovation campus followed, where numerous promising companies have already settled.
With Robert Rudolph, the management of the Innovaare park is getting a new and well-known face. Mr. Rudolph was previously employed as head of technology transfer at the Paul Scherrer Institute PSI and as a member of the executive board of the Swissmem industry association he was most recently responsible for the topics of digitalisation, innovation, research and start-ups. In this role, he became a expert on the Swiss innovation landscape and the needs of industry with regard to research and development.
Chairman of the Board of Directors Dr Christian Brönnimann expressed his thanks to Dr. Rechsteiner for his successful work in setting up the Park Innovaare generation project: "Thanks to Benno Rechsteiner's commitment in finding investors, the groundbreaking ceremony for the park was held and the first buildings were erected on a total area of 38,000 square metres. With Robert Rudolph at the helm, we now have a CEO with far reaching industrial contacts. We are convinced that Mr. Rudolph, with his background and network, brings the best prerequisites to lead the Park Innovaare into a successful future!"